UNSPSC 51271911: Piridocaine

This classification denotes an anesthetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 488S0H4SQF. European Medicines Agency schedules Piridocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09910MIG. Piridocaine generally arises in the molecular formula C14H20N2O2. The term PIRIDOCAINE is an International Non-Proprietary Name or INN. PIRIDOCAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule piridocaine under HS 29333999 and SITC 51574. As of Q4 2014, PIRIDOCAINE remains the US FDA Preferred Term for this commodity. Piridocaine bears US NLM identifiers UMLS ID C2827301 and NCI Concept Code C84065. SMILES: O(CCC1NCCCC1)C(=O)C1C(N)CCCC1.

UNSPSC 51271911 Piridocaine is a Commodity code representing pharmaceutical products that state and local governments procure through cooperative purchasing vehicles and direct supply agreements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, recently issued an RFP on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities in Minnesota and Oregon. The solicitation requires manufacturers to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with detailed product specifications including National Drug Codes (NDC), SKUs, UPCs, generic descriptions, strength, dosage form, and manufacturing locations. All products must comply with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), and vendors must maintain contractual relationships with at least two of the three authorized wholesalers. MMCAP uses cooperative purchasing to consolidate pharmaceutical procurement across multiple member jurisdictions, evaluating proposals primarily on price competitiveness (75 percent weight) alongside fixed pricing for the contract term, compliance with administrative data formats, EDI capability, and agreement to a 3 percent administrative fee.

MMCAP's RFP with a response deadline of March 26, 2026 represents the primary recent activity under this code. The two-year contract term runs through June 30, 2028 for new responders, with products required to be available in the marketplace by May 15, 2026 and effective July 1, 2026. Vendors must carry comprehensive insurance including $5 million commercial general liability and $2 million each in network security/privacy and professional liability coverage. The procurement does not identify specific dollar values or budget ranges, but vendors should anticipate a 3 percent administrative fee on all contract purchases and potential performance penalties ranging from $200 to $1,500 per violation for issues such as late reporting or missed onboarding timelines. Questions close February 18, 2026, and submissions are made through the ePro system using designated Excel spreadsheet formats converted to CSV.